

Disclosure of total number of voting rights and number of shares in the capital as of August 31st, 2023

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

Total number of shares	18,275,608
Number of real voting rights* (excluding treasury shares**)	18,214,454
Theoretical number of voting rights* (including treasury shares**)	18,252,408

(*) Class E preference shares are non-voting

(**) pursuant to article 223-11 of the AMF’s General Regulations



About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and iBiospy®, our AI-powered imaging platform for the development of software as medical devices (SaMD), help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI France and is listed on Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information: www.mediantechologies.com

Contacts

Median Technologies Emmanuelle Leygues Head of Corporate Marketing & Financial Communications +33 6 10 93 58 88 emmanuelle.leygues@mediantechnologies.com	Press - ALIZE RP Caroline Carmagnol +33 6 64 18 99 59 median@alizerp.com	Investors - ACTIFIN Ghislaine Gasparetto +33 6 21 10 49 24 ggasparetto@actifin.fr
---	--	---